Reprogramming drug discovery.

AI agents commercialize drug assets — 10x faster, 20x leaner.

Founded at Stanford. Backed by Y Combinator.

Why Convexia

Drug development is slow, fragmented, and increasingly expensive. Convexia is re-engineering this process using agentic software that reduces waste, increases speed, and uncovers hidden potential in preclinical pipelines.

The $1.6T Opportunity

Massive market with untapped potential for AI-driven drug discovery acceleration.

$1.6T

Global pharma market

$150B

Early-stage deal flow

$2.5B

Addressable segment

Asset Acquisition Speed

Traditional:
18 months
Convexia:
6 weeks
10x Faster

From months of manual due diligence to weeks of AI-powered analysis

We streamline drug development:

10x faster, 20x leaner.

Convexia's agentic platform moves drug assets through four intelligent stages, transforming how the industry sources and commercializes therapeutics.

🧭

Sourcing

10,000+ assets parsed monthly

AI agents scan global public & private data to identify overlooked assets.

Speed: Real-time scanning
Accuracy: 99.2% precision
🔬

Scientific Diligence

50+ heuristics per target

Automated review of mechanism, preclinical data, novelty, and signal strength.

Speed: Hours vs weeks
Accuracy: 95% signal detection
📊

Commercial Modeling

Instant multi-scenario TAM modeling

Evaluate IP, competitive landscape, and market access with minimal human input.

Speed: Instant analysis
Accuracy: Multi-scenario modeling
🤝

Business Development

Exit-ready in < 18 months

We match high-potential assets to downstream partners and manage the deal.

Speed: Rapid deal flow
Accuracy: 85% success rate

Closed-loop learning: Each deal informs our AI agents, making the next discovery even faster.

Hub & Spoke Model

We acquire promising early-stage drug assets, advance them through Phase 1 and 2 trials, and strategically exit to maximize returns.

🎯

Acquire

Source and purchase undervalued early-stage drug assets from academic institutions, biotechs, and pharma companies worldwide.

$50K-2MPre-clinicalHigh potential
🧪

Phase 1 Trials

Demonstrate safety and initial efficacy signals in human subjects, establishing proof-of-concept for the therapeutic approach.

20-100 patientsSafety focusBiomarker validation
📈

Phase 2 Trials

Validate efficacy in target patient populations while continuing to monitor safety and optimize dosing strategies.

100-300 patientsEfficacy focusRegulatory alignment
🚀

Strategic Exit

License or sell Phase 2-ready assets to pharmaceutical partners at premium valuations reflecting de-risked clinical profiles.

$50M-500M10-25x returnsRisk-adjusted

Result: Systematic value creation through clinical de-risking, transforming early-stage assets into validated, exit-ready therapeutics.

Built by Founders at the Frontier

Convexia was founded at Stanford by engineers and scientists passionate about bringing automation to biology.

Ayaan Parikh

Ayaan Parikh

CEO

Stanford engineer. YC alum. Previously led healthcare ventures at the intersection of behavioral science and software.

Rahul Vijayan

Rahul Vijayan

CTO

ML researcher and systems builder. Built agentic infrastructure for scientific exploration and drug discovery.

Supported by leading institutions in biotech and AI

🚀Y Combinator
🧬Stanford Bio-X
🏛️Stanford University

Let's Talk

We're actively seeking collaborators, investors, and discovery partners.